BiotechTube

VXA-A1.1 H1 Tablet Vaccine (small) + VXA-A1.1 H1 Tablet Vaccine (large)

Phase 1Completed
0 watching 0 views this week๐Ÿ’ค Quiet
25
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Seasonal Influenza Preventative Vaccine Pharmacodynamics

Conditions

Seasonal Influenza Preventative Vaccine Pharmacodynamics

Trial Timeline

Mar 31, 2017 โ†’ Apr 3, 2018

NCT ID
NCT03121339

About VXA-A1.1 H1 Tablet Vaccine (small) + VXA-A1.1 H1 Tablet Vaccine (large)

VXA-A1.1 H1 Tablet Vaccine (small) + VXA-A1.1 H1 Tablet Vaccine (large) is a phase 1 stage product being developed by Vaxart for Seasonal Influenza Preventative Vaccine Pharmacodynamics. The current trial status is completed. This product is registered under clinical trial identifier NCT03121339. Target conditions include Seasonal Influenza Preventative Vaccine Pharmacodynamics.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT03121339Phase 1Completed

Competing Products

20 competing products in Seasonal Influenza Preventative Vaccine Pharmacodynamics

See all competitors
ProductCompanyStageHype Score
Bilastine + Desloratadine + PlaceboYuhanPhase 3
77
ASP4070 + PlaceboAstellas PharmaPhase 2
52
S-555739 Dose 1 + S-555739 Dose 2 + Cetirizine HCl Dose 1 + S-555739 placebo + Cetirizine HCl placeboShionogiPhase 2
52
Cetirizine + High dose ONO-4053 + Low dose ONO-4053 + PlaceboOno PharmaceuticalPhase 2
52
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + PlaceboSumitomo PharmaPhase 3
77
80 mcg Ciclesonide + 160 mcg Ciclesonide + PlaceboSumitomo PharmaPhase 3
77
Ciclesonide HFA 160 ฮผg + Ciclesonide HFA 80 ฮผg + PlaceboSumitomo PharmaPhase 3
77
GSP 301-1 NS (QD) + GSP 301-2 NS (BID) + GSP 301 Placebo NS + Olopatadine HCl-1 NS (QD) + Olopatadine HCl-2 NS (BID) + Mometasone Furoate-1 NS (QD) + Mometasone Furoate-2 NS (BID)Glenmark PharmaceuticalsPhase 2
52
Molo 1 (also referred as GSP 301-2 NS) + Molo 2 (also referred as GSP 301-1 NS) + Placebo nasal spray + DYMISTA nasal spray + PATANASE nasal sprayGlenmark PharmaceuticalsPhase 2
52
JNJ38224342 + JNJ38224342/placebo + JNJ38224342/placebo + JNJ38224342/placeboJohnson & JohnsonPhase 1
33
Ciclesonide + PlaceboAstraZenecaPhase 3
77
Ciclesonide + PlaceboAstraZenecaPhase 3
77
Ciclesonide HFA + Ciclesonide HFA + Ciclesonide HFA + PlaceboAstraZenecaPhase 2
52
budesonide + PlaceboAstraZenecaPhase 2
52
Ciclesonide + PlaceboAstraZenecaPhase 3
77
Ciclesonide Nasal SprayAstraZenecaPhase 3
77
Budesonide + Fluticasone propionate + PlaceboAstraZenecaPhase 3
77
Ciclesonide + Ciclesonide PlaceboAstraZenecaPhase 3
77
loratadineMerckPre-clinical
23
MK0524MerckPhase 2
52

Other Products from Vaxart

Vapendavir + Vapendavir + PlaceboPhase 2
44
VXA-A1.1 + FluzoneยฎPhase 2
44
Vapendavir + Placebo Oral TabletPhase 2
44
VXA-CoV2-1.1-SPhase 2
44
BTA798 + PlaceboPhase 2
44